Results 51 to 60 of about 100,614 (290)

Gemcitabine exhibits a suppressive effect on pancreatic cancer cell growth by regulating processing of PVT1 to miR1207

Molecular Oncology, 2018
Gemcitabine serves as a first‐line chemotherapy agent for advanced pancreatic cancer (PC). However, the molecular basis by which gemcitabine exerts its effects is not well‐established, and the targeted genetic pathways remain unclear.
Lei You, Huanyu Wang, Gang Yang, Fangyu Zhao, Jingcheng Zhang, Ziwen Liu, Taiping Zhang, Zhiyong Liang, Changzheng Liu, Yupei Zhao   +9 more
doaj   +1 more source

THE DIFFERENCES OF APOPTOSIS EFFECTS BETWEEN COMBINATION OF MELOXICAM WITH GEMCITABINE-CARBOPLATIN CHEMOTHERAPY COMPARED TO GEMCITABINE-CARBOPLATIN CHEMOTHERAPY ALONE IN UROTHELIAL CARCINOMA CULTURE CELLS

Jurnal Urologi Indonesia, 2019
Objective: To determine the differences of apoptosis effect between the combination of meloxicam and gemcitabine-carboplatin compared to gemcitabine-carboplatin alone as the standard of chemotherapy care in urothelial carcinoma culture cells.
Ananta Cahyo Nugroho, Lukman Hakim, Wahjoe Dajtisoesanto, Doddy M Soebadi   +3 more
doaj   +1 more source

A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. [PDF]

PLoS ONE, 2013
Gemcitabine is among the most efficacious and widely used antimetabolite agents. Its molecular targets are ribonucleotide reductase M1 (RRM1) and elongating DNA.
Jun Zhou, Zhengming Chen, Agnes Malysa, Xin Li, Paula Oliveira, Yingtao Zhang, Gerold Bepler   +6 more
doaj   +1 more source

METTL5 Enables Immune Evasion of Liver Cancer via Chemokine mRNA Translation Regulation

Advanced Science, EarlyView.
METTL5 reshapes the tumor immune microenvironment through ribosome 18S rRNA m6A modification to regulate the translation of chemokine mRNA. Targeting METTL5‐mediated immunosuppression unleashes anti‐tumor immunity and improves the efficacy of anti‐PD‐1 therapy.
Shuang Li, Xiao Zhao, Tongtong Song, Qiaoyi Chen, Yanqing Wu, Yuting Zhang, Jingying Chen, Yifan Wu, Bin Li, Xinyue Zhang, Zihao Dai, Lixia Xu, Yubin Xie, Alfred Sze‐Lok Cheng, Jianping Guo, Ming Kuang, Shuibin Lin, Zhenwei Peng, Sui Peng, Xuezhen Zeng   +19 more
wiley   +1 more source

Metabolic Reprogramming of T Cells by Dual UCP2 and IL‐17 Blockade Enhances Immunity Against Pancreatic Cancer

Advanced Science, EarlyView.
This study demonstrates that dual UCP2/IL‐17 blockade reprograms T‐cell metabolism to overcome PDAC immunosuppression. Genipin‐mediated UCP2 inhibition enhances CD8⁺ T‐cell IFN‐γ via IL‐12R/STAT4/mTOR signaling and mitochondrial OXPHOS. Combined IL‐17 depletion amplifies Tc1/Th1 responses, reduces MDSCs, and prolongs survival in PDAC models ...
Chuan‐Teng Liu, Chun‐Chieh Yeh, Tsai‐Chen Wu, Chia‐Hsin Lin, Yi‐Ting Kuo, Yoichiro Iwakura, Yuan‐Ji Day, Charles Drake, Vedran Radojcic, Ying‐Chyi Song, Heng‐Hsiung Wu, Hung‐Rong Yen   +11 more
wiley   +1 more source

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine vs FOLFIRINOX or gemcitabine for the first-line treatment of metastatic pancreatic adenocarcinoma in a US community setting

Cancer Management and Research, 2017
Fadi Braiteh,1 Manish B Patel,2 Monika Parisi,2 Quanhong Ni,2 Siyeon Park,2,3 Claudio Faria2 1Comprehensive Cancer Centers of Nevada, University of Nevada School of Medicine, Las Vegas, NV, 2Celgene Corporation, Summit, NJ, 3The Ohio State University ...
Braiteh F, Patel MB, Parisi M, Ni Q, Park S, Faria C   +5 more
doaj  

NIR‐Activatable Domino Cascade Catalysis Nanozyme Reactor for Multi‐Mechanism Synergistic Immunotherapy in Bladder Cancer

Advanced Science, EarlyView.
This study presents an intravesical delivery strategy of ferroptosis‐ and immunity‐inducing nanozyme‐loaded thermoresponsive hydrogels (FMCC@PNH) for enhanced bladder cancer therapy. Abstract Current intravesical therapies for bladder cancer after resection are limited by poor tissue penetration, off‐target effects, and insufficient efficacy.
Yongnan Jiang, Qingling Zhang, Yuhan Zhang, Xinlu Yu, Bo Jia, Yulong Dong, Yalong Wu, Kelong Fan, Xinquan Gu, Lei Ji, Wei Jiang, Bin Liu   +11 more
wiley   +1 more source

In Situ Lipoprotein‐seeking Dye for in Vivo Real‐Time Imaging of Lipid Dysregulation Diseases

Advanced Science, EarlyView.
This study develops lipoprotein‐seeking NIR‐II dyes that specifically bind circulating lipoproteins. These dyes form ultra‐stable complexes with endogenous lipoprotein, enabling real‐time, high‐contrast imaging of fatty liver and atherosclerotic plaques. Tunable binding kinetics allow customized imaging windows.
Yijing Du, Zetao Dang, Baofeng Xu, Jiajun Xu, Dan Wang, Yuewei Zhang, Shoujun Zhu   +6 more
wiley   +1 more source

Early Detection of Chemotherapy‐Induced Glucose Metabolic Alterations in Bladder Carcinoma Using Deuterium (2H) Metabolic Imaging: in Vitro and in Vivo Assessments

Advanced Science, EarlyView.
This study presents the first application of deuterium metabolic imaging (DMI) for assessing therapeutic response in bladder cancer. Employing [2,3,4,6,6′‐2H5]‐D‐glucose, DMI successfully identified chemotherapy‐induced suppression of glycolysis both in vitro and in vivo.
Lingmin Kong, Ganghan Yang, Bei Weng, Zhihua Wen, Joshua D. Kaggie, Qian Cai, Qian Wan, Cuien Zheng, Feng Du, Ye Li, Xin Liu, Ferdia A. Gallagher, Yan Guo, Shi‐Ting Feng, Chao Zou, Huanjun Wang   +15 more
wiley   +1 more source

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine

International Journal of Nanomedicine, 2019
Wenchao Liu1,2, Yujia Mao1,2, Xiaoyi Zhang1,2, Yaonan Wang1,2, Jianhui Wu1,2, Shurui Zhao1,2, Shiqi Peng1,2, Ming Zhao1–3 1Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, Department of Medicinal Chemistry, School of ...
Liu W, Mao Y, Zhang X, Wang Y, Wu J, Zhao S, Peng S, Zhao M   +7 more
doaj